Protara Therapeutics (TARA) Net Cash Flow (2013 - 2026)

Protara Therapeutics' Net Cash Flow history runs 14 years deep, the most recent figure standing at -$34.9 million for Q1 2026.

• In Q1 2026, Net Cash Flow rose 51.05% year-over-year to -$34.9 million; the TTM figure through Mar 2026 stood at -$76.7 million (down 295.57% YoY), while the FY2025 annual figure was -$113.1 million, down 191.83% from the prior year.
• Net Cash Flow was -$34.9 million for Q1 2026 at Protara Therapeutics, down from $37.1 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $111.0 million in Q4 2024 to a low of -$71.3 million in Q1 2025.
• Historically, Net Cash Flow has averaged -$1.2 million across 5 years, with a median of -$210000.0 in 2023.
• Biggest YoY gain for Net Cash Flow was 1808.58% in 2024; the steepest drop was 17911.43% in 2024.
• A 5-year view of Net Cash Flow shows it stood at -$23.4 million in 2022, then soared by 124.89% to $5.8 million in 2023, then surged by 1808.58% to $111.0 million in 2024, then tumbled by 66.58% to $37.1 million in 2025, then slumped by 194.11% to -$34.9 million in 2026.
• The last three Net Cash Flow figures came in at -$34.9 million (Q1 2026), $37.1 million (Q4 2025), and -$18.9 million (Q3 2025), per Business Quant data.